HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Case report study of the first five COVID-19 patients treated with remdesivir in France.

Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified as the virus responsible for the coronavirus disease 2019 (COVID-19) outbreak worldwide. Data on treatment are scare and parallels have been made between SARS-CoV-2 and other coronaviruses. Remdesivir is a broad-spectrum antiviral with efficient in vitro activity against SARS-CoV-2. Evidence of clinical improvement in patients with severe COVID-19 treated with remdesivir is controversial. The aim of this study was to describe the clinical outcomes and virological monitoring of the first five COVID-19 patients admitted to the intensive care unit of Bichat-Claude Bernard University Hospital, Paris, France, for severe pneumonia related to SARS-CoV-2 and treated with remdesivir. Quantitative reverse transcription PCR was used to monitor SARS-CoV-2 in blood plasma and the lower and upper respiratory tract. Among the five patients treated, two needed mechanical ventilation and one needed high-flow cannula oxygen. A significant decrease in SARS-CoV-2 viral load in the upper respiratory tract was observed in most cases, but two patients died with active SARS-CoV-2 replication in the lower respiratory tract. Plasma samples were positive for SARS-CoV-2 in only one patient. Remdesivir was interrupted before the initialy planned duration in four patients, two because of alanine aminotransferase elevations (3 to 5 normal range) and two because of renal failure requiring renal replacement. This case series of five COVID-19 patients requiring intensive care unit treatment for respiratory distress and treated with remdesivir, highlights the complexity of remdesivir use in such critically ill patients.
AuthorsMarie Dubert, Benoit Visseaux, Valentina Isernia, Lila Bouadma, Laurène Deconinck, Juliette Patrier, Paul-Henri Wicky, Diane Le Pluart, Laura Kramer, Christophe Rioux, Quentin Le Hingrat, Nadhira Houhou-Fidouh, Yazdan Yazdanpanah, Jade Ghosn, Francois-Xavier Lescure
JournalInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (Int J Infect Dis) Vol. 98 Pg. 290-293 (Sep 2020) ISSN: 1878-3511 [Electronic] Canada
PMID32619764 (Publication Type: Case Reports)
CopyrightCopyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Chemical References
  • Antiviral Agents
  • remdesivir
  • Adenosine Monophosphate
  • Alanine
Topics
  • Adenosine Monophosphate (adverse effects, analogs & derivatives, therapeutic use)
  • Adult
  • Aged
  • Aged, 80 and over
  • Alanine (adverse effects, analogs & derivatives, therapeutic use)
  • Antiviral Agents (adverse effects, therapeutic use)
  • Betacoronavirus (drug effects, physiology)
  • COVID-19
  • Coronavirus Infections (drug therapy, virology)
  • Female
  • France
  • Hospitalization
  • Humans
  • Male
  • Pandemics
  • Pneumonia, Viral (drug therapy, virology)
  • SARS-CoV-2
  • Viral Load (drug effects)
  • Withholding Treatment

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: